I know everything I need to know about someone based on whether they liked this movie. I don't disrespect them or dislike them. I just know.
18.02.2026 22:24
👍 0
🔁 0
💬 0
📌 0
I know everything I need to know about someone based on whether they liked this movie. I don't disrespect them or dislike them. I just know.
Counterpoint:
Don’t upload your medical records to any LLM.
That’s fucking insane.
Yeah, this is a good one. We might be able to trust the machines, but not the people building the machines.
Wow. Only 15. Thank you so much for sharing this.
Just keep doing it. I got intrepid and then laughable. 🤷🏻♀️
Congratulations, Lisa. Can’t wait to hear more about your plans.
What a mess.
Review highlights gaps and opportunities to expand cancer clinical trials in Latin America, a region with rising cancer burden but <2% of global trial activity.
Read more: buff.ly/tVPqGO3
#GlobalOncology #ClinicalTrials #LatinAmerica
JCO Journals are now on BlueSky! Give us a follow. @jco-asco.bsky.social @pamelakunzmd.bsky.social @ethicsdoctorp.bsky.social @hemoncwarner.bsky.social @kvanloonmd.bsky.social
Oh, I agree that the hammer could have fallen at any point. I do think that new pressures on Google in the search area raise the question a little more acutely.
Might Google Scholar be headed to the Google Graveyard? hannahshelley.neocities.org/blog/2025_08...
Can't be, Paul. Schools are gun-free zones and the NRA/GOP is constantly telling us that this makes them LESS safe.
A pleasure and an honor to join @fumikochino.bsky.social & Dr. Ethan Ludmir in this @ascocancer.bsky.social conversation on incomplete reporting and toxicity- minimizing language in oncology! 💗
I don't agree with their peer review model, but the premise here is correct. There are rules of indexing and citation counting that are keeping journals from transforming into modern publication systems.
FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers
insights.citeline.com/pink-sheet/a...
May the odds be ever in your favor.
4% payline at the NCI.
www.cancer.gov/grants-train...
In an unprecedented move, the NIH will soon disinvite dozens of scientists who were about to take positions on advisory councils that make final decisions on grant applications for the US agency, Nature has learnt.
go.nature.com/3TEw7GN
Can the next governor replace those people on the board? Seems it’s in Virginia residents best interest to have a world class public institution.
Agree. At least a decade of pushing our kids to STEM only. Result: few can critically read or write, entry level computer science/coding jobs were the 1st to get cut with AI, decrease in kids wanting to be physicians.
Yep. Prestige costs money to create (literally: highly-selective journals are more expensive to run in part because of their selectivity, not to mention their staff). And, if gold OA is to be the model, then author or their funders are agreeing to pay per paper for that prestige.
We have life saving cancer drugs and life threatening shortages. See our new op ed with potential solutions in @jco-asco.bsky.social
@lymphomadoc.bsky.social
@ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
There's also a helpful criticism here that, if we have to constantly and meticulously double check the work of AI then is it a tool that really saves us time and effort? And, given that cost/benefit ratio, what are the actual use cases that make using it worthwhile?
‼️ #ASCO25 simultaneous publication by Jacobs et al:
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation. Read the full article: ascopubs.org/doi/10.1200/...
For breaking news and expert analysis during #ASCO25, turn to #ASCODailyNews! During and after the Meeting, ASCO Daily News has coverage of all the practice-changing research being presented. Bookmark us now: dailynews.ascopubs.org/meetings/asc... #oncsky
The @ascocancer.bsky.social Ed Book is the highest-quality, peer-reviewed, FREE #oncology #MedEd ever. Whether or not you’re at #ASCO25, don’t miss this resource, #OncSky #MedSky, #MedStudentSky! Drop a 📌 in the comments to bookmark the link for later.
ascopubs.org/toc/edbk/cur...
#OncoAlert
Don't miss it! #ASCODailyNews has your exclusive advanced coverage of important abstracts being presented at #ASCOAM dailynews.ascopubs.org/meetings/asc...
Just announced: ASCO and Google Cloud launch the ASCO Guidelines Assistant, an AI tool for fast access to ASCO's trusted and expert-developed clinical cancer guidelines. Read more in @statnews.com
Exciting news! Making ASCO expert, evidence-based treatment guidelines easier than ever to access.
The first of many simultaneous publications out today in #JCOGO. More to come! #ASCO25
Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social